Ibondem (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to bone mineral at sites of active remodeling. When osteoclasts attach to these sites, the drug is taken up and inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast function and inducing apoptosis, which leads to decreased bone resorption.

The dosing regimen for Ibondem is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and treatment goals. The prescriber will decide the appropriate dose, infusion rate, and frequency according to approved guidelines.

Safety of ibandronic acid in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women of childbearing potential should use effective contraception during treatment.

To order Ibondem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Ibondem (ibandronic acid) is administered intravenously and has a long skeletal retention time, allowing less frequent dosing compared with oral bisphosphonates. Compared with other IV agents such as zoledronic acid, ibandronate may have a slightly lower incidence of acute phase reactions, but efficacy and safety profiles are broadly similar.

Ibondem should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discolored or contains particles.

Ibondem is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically administered over a short period, following verification of the patient’s renal function and calcium status, and patients are monitored for any acute reactions during and after the infusion.

Serious risks include acute renal impairment, severe hypocalcemia, osteonecrosis of the jaw, and atypical femur fractures. Patients should be evaluated for renal function before each dose, maintain adequate calcium and vitamin D intake, and report any persistent jaw pain or unusual thigh pain promptly.

Ibondem is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to ibandronic acid or any formulation components, and those with existing hypocalcemia. Caution is also advised for patients with active dental infections or recent invasive dental procedures.